Sinopharm BIBP COVID-19 vaccine

For other uses, see Sinopharm COVID-19 vaccine.

BBIBP-CorV
A vial of the BBIBP-CorV COVID-19 vaccine
Vaccine description
TargetSARS-CoV-2
Vaccine typeInactivated
Clinical data
Other namesZhong'aikewei (Chinese: 众爱可维), Hayat-Vax
Routes of
administration		Intramuscular
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
Part of a series on the
COVID-19 pandemic
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Scientifically accurate atomic model of the external structure of SARS-CoV-2. Each "ball" is an atom.
Timeline
2019
2020
2021
2022
2023
Locations
By country and territory
By conveyance
International response
National responses
Medical response
Vaccines
Current vaccines
Variants
Variants of concern
Other variants
Economic impact and recession
By country
By sport
Impacts
Long COVID
Society
Politics
virus icon COVID-19 portal

The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV,[2] the Sinopharm COVID-19 vaccine,[3] or BIBP vaccine,[3][4][5] is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products,[6] resulting in the two different acronyms BBIBP and BIBP for the same vaccine). It completed Phase III trials in Argentina, Bahrain, Egypt, Morocco, Pakistan, Peru, and the United Arab Emirates (UAE) with over 60,000 participants.[7] BBIBP-CorV shares similar technology with CoronaVac and Covaxin, other inactivated virus vaccines for COVID-19.[8][9] Its product name is SARS-CoV-2 Vaccine (Vero Cell),[10][11][12] not to be confused with the similar product name of CoronaVac.[13][14]

Peer-reviewed results published in JAMA of Phase III trials in United Arab Emirates and Bahrain showed that the vaccine is 78.1% effective against symptomatic cases and 100% against severe cases (21 cases in vaccinated group vs. 95 cases in placebo group).[15] In December 2020, the UAE previously announced interim results showing 86% efficacy.[16]

While mRNA vaccines like the Pfizer–BioNTech COVID-19 vaccine and Moderna COVID-19 vaccine showed higher efficacy of over 90%, those present distribution challenges for some nations as they require deep-freeze facilities and trucks. The BIBP vaccine could be transported and stored at normal refrigerated temperatures.[17]

The vaccine is being used in vaccination campaigns by certain countries in Asia,[18][19][20] Africa,[21][22][23] South America,[24][25][26] and Europe.[27][28][29] Sinopharm expects to produce one billion doses of the vaccine in 2021.[30] By May, Sinopharm had supplied 200 million doses.[31]

On 7 May 2021, the World Health Organization approved the BIBP vaccine for use in COVAX.[32][33] Sinopharm has signed purchase agreements for 170 million doses from COVAX.[34]

The similarly named Sinopharm WIBP COVID-19 vaccine is also an inactivated virus vaccine.

A vaccination certificate of BBIBP-CorV (Beijing Institute of Biological Products, Sinopharm).
  1. ^ "Covax Facility" (in Portuguese). Federal government of Brazil. Brazilian Health Regulatory Agency. 25 June 2021. Retrieved 20 November 2021.
  2. ^ Cite error: The named reference Xia_2021 was invoked but never defined (see the help page).
  3. ^ a b "The Sinopharm COVID-19 vaccine: What you need to know". World Health Organization. 10 May 2021. Retrieved 5 July 2021.
  4. ^ Nguyen S (5 June 2021). "Coronavirus: Vietnam approves Sinopharm's vaccine, but will people take it?". South China Morning Post. Retrieved 5 July 2021.
  5. ^ Lahiri T, Li J (16 June 2021). "What we now know about the efficacy of China's Covid-19 vaccines". Quartz. Retrieved 5 July 2021.
  6. ^ "WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations". World Health Organization. 7 May 2021. Retrieved 3 July 2021.
  7. ^ "China Sinopharm's coronavirus vaccine taken by about a million people in emergency use". Reuters. 19 November 2020. Retrieved 9 December 2020.
  8. ^ Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
  9. ^ Cite error: The named reference Corum_2021 was invoked but never defined (see the help page).
  10. ^ "WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations". World Health Organization. 7 May 2021. Retrieved 13 June 2021. The Sinopharm product is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell).
  11. ^ Chen W, Al Kaabi N (18 July 2020). "A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells)". Chinese Clinical Trial Registry. Archived from the original on 11 October 2020. Retrieved 13 June 2021.
  12. ^ Yang Y. "A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above". Archived from the original on 14 September 2020. Retrieved 13 June 2021.
  13. ^ "Sinovac's Coronavac™, SARS-CoV-2 Vaccine (Vero Cell), Inactivated, Announces Approval for Phase I/II Clinical Trial in Adolescents and Children" (Press release). Beijing: Bloomberg. Business Wire. 23 September 2020. Retrieved 13 June 2021.
  14. ^ "A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Inactivated (Vero Cell) Vaccine in the Elderly 60–80 Years of Age, Coronovac ENCOV19 Study". registry.healthresearch.ph. Philippine Health Research Registry. Retrieved 13 June 2021.
  15. ^ Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X (26 May 2021). "Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial". JAMA. 326 (1): 35–45. doi:10.1001/jama.2021.8565. PMC 8156175. PMID 34037666.
  16. ^ "UAE: Ministry of Health announces 86 per cent vaccine efficacy". gulfnews.com. 9 December 2020. Retrieved 13 December 2020.
  17. ^ "China State-Backed Covid Vaccine Has 86% Efficacy, UAE Says". Bloomberg.com. 9 December 2020. Retrieved 9 December 2020.
  18. ^ Cite error: The named reference Liu_2020 was invoked but never defined (see the help page).
  19. ^ Turak N (18 January 2021). "The UAE is on track to have half its population vaccinated by the end of March". CNBC. Retrieved 21 January 2021.
  20. ^ Cite error: The named reference Dawn.com_2021 was invoked but never defined (see the help page).
  21. ^ Cite error: The named reference Reuters_2021 was invoked but never defined (see the help page).
  22. ^ Dumpis T (27 January 2021). "Morocco Receives Half a Million Doses of Chinese Sinopharm Vaccine". Morocco World News. Retrieved 28 January 2021.
  23. ^ "Zimbabwe starts administering China's Sinopharm vaccines". thestar.com. 18 February 2021. Retrieved 20 February 2021.
  24. ^ "Argentina autoriza la vacuna china Sinopharm para mayores de 60 años". El Comercio. 25 March 2021. Retrieved 26 March 2021.
  25. ^ Cite error: The named reference Aquino_2021 was invoked but never defined (see the help page).
  26. ^ "Bolivia begins inoculation with Sinopharm jabs | The Star". www.thestar.com.my. Retrieved 28 February 2021.
  27. ^ "Serbia Becomes First European Nation To Use China's Sinopharm Vaccine". Radio Free Europe/Radio Liberty. 20 January 2021. Retrieved 21 January 2021.
  28. ^ "Hungary first EU nation to use China's Sinopharm vaccine against COVID". euronews. 24 February 2021. Retrieved 26 February 2021.
  29. ^ "Belarus begins COVID-19 vaccinations with Chinese shots". eng.belta.by. 15 March 2021. Retrieved 16 March 2021.
  30. ^ "Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World. 5 February 2021. Retrieved 28 February 2021.
  31. ^ "WHO approves Sinopharm vaccine in potential boost to COVAX pipeline". Reuters. 7 May 2021. Retrieved 14 May 2021.
  32. ^ "WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations" (Press release). World Health Organization (WHO). 7 May 2021. Retrieved 7 May 2021.
  33. ^ Taylor A (7 May 2021). "WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine". The Washington Post. Retrieved 7 May 2021.
  34. ^ "Chinese drugmakers agree to supply more than half a billion vaccines to COVAX". Reuters. 12 July 2021. Retrieved 13 July 2021.